Good Morning My Friends,
Thought the following information may be of some interest and benefit to
you.
multi-institutional clinical study has demonstrated
that a combination of Rituxan, a monoclonal antibody,
and the systemic standard dose chemotherapy regimen
is safe and has a 95 percent overall response rate
in patients with non-Hodgkin's lymphoma.
God Bless
marty auslande
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
